Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

NCT00220402 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer